UBS Lowers Estimates on Cadence Pharma (CADX); Ofirmev’s Sales Remain Disappointing
Tweet Send to a Friend
UBS maintains a 'Neutral' on Cadence Pharma (NASDAQ: CADX) price target of $3.00 (from $4.00).
Analyst, Ami Fadia, said ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Analyst, Ami Fadia, said ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
